冠状动脉支架置入术后的抗凝治疗。
Anticoagulation after intracoronary stent insertion.
作者信息
Brack M J, Hubner P J, Gershlick A H
机构信息
Academic Department of Cardiology, University of Leicester, Glenfield General Hospital.
出版信息
Br Heart J. 1994 Sep;72(3):294-6. doi: 10.1136/hrt.72.3.294.
Abstract
Stents rarely thrombose in the first 24 hours after implantation; secondly, heparin has some influence on the extrinsic pathway. Additionally, if too much heparin is present it interferes with the INR, and the half life of prothrombin suggests that the patient should be anticoagulated with heparin for up to 96 hours after starting warfarin. This is the evidence on which our standard protocol is based.
摘要
支架在植入后的最初24小时内很少形成血栓；其次，肝素对外源性途径有一定影响。此外，如果存在过多肝素，会干扰国际标准化比值（INR），并且凝血酶原的半衰期表明，在开始使用华法林后，患者应使用肝素抗凝长达96小时。这就是我们标准方案所依据的证据。
相似文献
1
Anticoagulation after intracoronary stent insertion.冠状动脉支架置入术后的抗凝治疗。
Br Heart J. 1994 Sep;72(3):294-6. doi: 10.1136/hrt.72.3.294.
2
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Sangre (Barc). 1997 Oct;42(5):387-90.
3
Anticoagulation interruptus: not without risk.抗凝中断：并非没有风险。
Circulation. 2004 Sep 21;110(12):1518-9. doi: 10.1161/01.CIR.0000143548.75223.C2.
4
Rationale for low-molecular weight heparin in coronary stenting.低分子量肝素用于冠状动脉支架置入术的理论依据。
Am Heart J. 1997 Nov;134(5 Pt 2):S81-7.
5
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.对于使用 HeartMate II 左心室辅助系统的患者，术后可能不需要肝素即可过渡到长期华法林治疗。
J Heart Lung Transplant. 2010 Jun;29(6):616-24. doi: 10.1016/j.healun.2010.02.003. Epub 2010 Apr 18.
6
7
Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
Cathet Cardiovasc Diagn. 1996 Apr;37(4):355-9. doi: 10.1002/(SICI)1097-0304(199604)37:4<355::AID-CCD1>3.0.CO;2-A.
8
9
[-Anticoagulation after intracoronary stent implantation-].
Herz. 1996 Feb;21(1):60-3.
10
[Emergency intracoronary stent implantation: complications and experiences with 124 patients].
Z Kardiol. 1994 May;83(5):327-35.
引用本文的文献
1
Trends in Dual Antiplatelet Therapy Use for Neurointerventional Procedures for the Management of Intracranial Aneurysms.用于颅内动脉瘤管理的神经介入手术双重抗血小板治疗的使用趋势。
Biomedicines. 2023 Aug 9;11(8):2234. doi: 10.3390/biomedicines11082234.
2
Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.心脏导管实验室中的抗栓治疗：聚焦于抗血小板药物。
Curr Cardiol Rep. 2000 Sep;2(5):386-94. doi: 10.1007/s11886-000-0051-0.
3
Antiplatelet therapy following stent deployment.
Heart. 1997 Oct;78 Suppl 2(Suppl 2):24-6. doi: 10.1136/hrt.78.suppl_2.24.
4
Coronary artery stenting with high-pressure post-dilation followed by adjunctive thrombolysis after failed coronary angioplasty for acute myocardial infarction: report of three cases.
Clin Cardiol. 1997 Apr;20(4):398-401. doi: 10.1002/clc.4960200418.
本文引用的文献
1
SURVIVAL TIME OF PROTHROMBIN AND FACTORS VII, IX AND X AFTER COMPLETELY SYNTHESIS BLOCKING DOSES OF COUMARIN DERIVATIVES.香豆素衍生物完全合成阻断剂量后凝血酶原及因子VII、IX和X的存活时间
Br J Haematol. 1963 Oct;9:506-12. doi: 10.1111/j.1365-2141.1963.tb05475.x.
2
Prothrombin fragment F1 + 2 concentrations for monitoring anticoagulation therapy with heparin.
Int J Cardiol. 1993 Jan;38(1):57-61. doi: 10.1016/0167-5273(93)90204-t.
3
Monitoring effects of oral anticoagulants during treatment with heparin.在肝素治疗期间监测口服抗凝剂的效果。
Br Med J (Clin Res Ed). 1984 Jan 21;288(6412):191. doi: 10.1136/bmj.288.6412.191.
4
Determinants of the response to oral anticoagulant drugs in man.人体口服抗凝药物反应的决定因素。
Pharmacol Rev. 1970 Mar;22(1):35-96.
5
Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.口服抗凝剂对血栓形成素质患者血液中止血系统激活的抑制作用。
J Clin Invest. 1987 Dec;80(6):1535-44. doi: 10.1172/JCI113239.
6
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.维生素K1 2,3-环氧化物还原酶的抑制与华法林导致的凝血因子活性降低之间的关系。
Br J Clin Pharmacol. 1988 Jan;25(1):1-7. doi: 10.1111/j.1365-2125.1988.tb03274.x.
7
The mode of action of heparin in plasma.肝素在血浆中的作用方式。
Thromb Haemost. 1988 Dec 22;60(3):457-62.
8
Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa.普通肝素对凝血酶催化的凝血放大反应的抑制作用比对Xa因子催化的反应更有效。
Biochem J. 1989 Jan 1;257(1):143-50. doi: 10.1042/bj2570143.
9
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin.抑制凝血酶依赖性正反馈反应对于肝素抗凝作用的发挥至关重要。
Biochem J. 1987 Apr 15;243(2):579-88. doi: 10.1042/bj2430579.
10
Oral anticoagulant drugs.
N Engl J Med. 1991 Jun 27;324(26):1865-75. doi: 10.1056/NEJM199106273242606.
Zotero 插件